Furthermore, in patients with HR+/HER2− tumours (n = 75), the detection rate was 36% in the paper by Kruijff et al, which is also comparable with our recently published data,33 detecting AR + CTCs in more than 20% of the 35 analysed HR+/HER2− patients in the follow‐up of the disease. The gene discussed is AR; the disease is neoplasm.